These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 10632670)
1. Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients. Otsuki T; Tomokuni A; Sakaguchi H; Aikoh T; Matsuki T; Isozaki Y; Hyodoh F; Ueki H; Kusaka M; Kita S; Ueki A Clin Exp Immunol; 2000 Feb; 119(2):323-7. PubMed ID: 10632670 [TBL] [Abstract][Full Text] [Related]
2. Detection of alternatively spliced variant messages of Fas gene and mutational screening of Fas and Fas ligand coding regions in peripheral blood mononuclear cells derived from silicosis patients. Otsuki T; Sakaguchi H; Tomokuni A; Aikoh T; Matsuki T; Isozaki Y; Hyodoh F; Kawakami Y; Kusaka M; Kita S; Ueki A Immunol Lett; 2000 May; 72(2):137-43. PubMed ID: 10841950 [TBL] [Abstract][Full Text] [Related]
3. Soluble Fas mRNA is dominantly expressed in cases with silicosis. Otsuki T; Sakaguchi H; Tomokuni A; Aikoh T; Matsuki T; Kawakami Y; Kusaka M; Ueki H; Kita S; Ueki A Immunology; 1998 Jun; 94(2):258-62. PubMed ID: 9741350 [TBL] [Abstract][Full Text] [Related]
4. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Lee CS; Hu CY; Tsai HF; Wu CS; Hsieh SL; Liu LC; Hsu PN Clin Exp Immunol; 2008 Mar; 151(3):383-90. PubMed ID: 18190609 [TBL] [Abstract][Full Text] [Related]
5. Serum levels of soluble Fas ligand in patients with silicosis. Tomokuni A; Otsuki T; Isozaki Y; Kita S; Ueki H; Kusaka M; Kishimoto T; Ueki A Clin Exp Immunol; 1999 Dec; 118(3):441-4. PubMed ID: 10594565 [TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Takahama Y; Yamada Y; Emoto K; Fujimoto H; Takayama T; Ueno M; Uchida H; Hirao S; Mizuno T; Nakajima Y Gastric Cancer; 2002; 5(2):61-8. PubMed ID: 12111580 [TBL] [Abstract][Full Text] [Related]
7. [Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof]. Shen HW; Wu YL; Peng SY Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):744-7. PubMed ID: 12899749 [TBL] [Abstract][Full Text] [Related]
8. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Tsuji S; Hosotani R; Yonehara S; Masui T; Tulachan SS; Nakajima S; Kobayashi H; Koizumi M; Toyoda E; Ito D; Kami K; Mori T; Fujimoto K; Doi R; Imamura M Int J Cancer; 2003 Aug; 106(1):17-25. PubMed ID: 12794752 [TBL] [Abstract][Full Text] [Related]
9. [Studies on Fas ligand expression in patients with systemic lupus erythematosus]. Feng Y Hokkaido Igaku Zasshi; 1997 Jul; 72(4):443-55. PubMed ID: 9266252 [TBL] [Abstract][Full Text] [Related]
10. Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Ohshima K; Haraoka S; Sugihara M; Suzumiya J; Kawasaki C; Kanda M; Kikuchi M Cancer Lett; 2000 Nov; 160(1):89-97. PubMed ID: 11098089 [TBL] [Abstract][Full Text] [Related]
11. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Hayashi S; Miura Y; Nishiyama T; Mitani M; Tateishi K; Sakai Y; Hashiramoto A; Kurosaka M; Shiozawa S; Doita M Arthritis Rheum; 2007 Apr; 56(4):1067-75. PubMed ID: 17393415 [TBL] [Abstract][Full Text] [Related]
12. Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma. Arakawa Y; Tachibana O; Hasegawa M; Miyamori T; Yamashita J; Hayashi Y Acta Neuropathol; 2005 Mar; 109(3):294-8. PubMed ID: 15627206 [TBL] [Abstract][Full Text] [Related]
13. Correlation between expression of DcR3 on tumor cells and sensitivity to FasL. Li W; Zhang C; Chen C; Zhuang G Cell Mol Immunol; 2007 Dec; 4(6):455-60. PubMed ID: 18163957 [TBL] [Abstract][Full Text] [Related]
14. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT. Wroblewski VJ; Witcher DR; Becker GW; Davis KA; Dou S; Micanovic R; Newton CM; Noblitt TW; Richardson JM; Song HY; Hale JE Biochem Pharmacol; 2003 Feb; 65(4):657-67. PubMed ID: 12566095 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. Shen HW; Gao SL; Wu YL; Peng SY World J Gastroenterol; 2005 Oct; 11(38):5926-30. PubMed ID: 16273601 [TBL] [Abstract][Full Text] [Related]
17. DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus. Han B; Bojalil R; Amezcua-Guerra LM; Springall R; Valderrama-Carvajal H; Wu J; Luo H Int Immunol; 2008 Aug; 20(8):1067-75. PubMed ID: 18562337 [TBL] [Abstract][Full Text] [Related]
18. TNFSF/TNFRSF cytokine gene expression in sickle cell anemia: Up-regulated TNF-like cytokine 1A (TL1A) and its decoy receptor (DcR3) in peripheral blood mononuclear cells and plasma. Safaya S; Alfarhan M; Sulaiman A; Alsulaiman A; Al-Ali A Cytokine; 2019 Nov; 123():154744. PubMed ID: 31255916 [TBL] [Abstract][Full Text] [Related]
19. Alterations of Fas and Fas-related molecules in patients with silicosis. Otsuki T; Miura Y; Nishimura Y; Hyodoh F; Takata A; Kusaka M; Katsuyama H; Tomita M; Ueki A; Kishimoto T Exp Biol Med (Maywood); 2006 May; 231(5):522-33. PubMed ID: 16636300 [TBL] [Abstract][Full Text] [Related]
20. Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development. Chen C; Zhang C; Zhuang G; Luo H; Su J; Yin P; Wang J Cancer Invest; 2008 Dec; 26(10):965-74. PubMed ID: 19093253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]